Enjoy complimentary customisation on priority with our Enterprise License!
Hyperkalemia is a medical condition in which the level of potassium in the blood stream increases and is categorized into mild hyperkalemia, moderate hyperkalemia, and severe hyperkalemia. Severe hyperkalemia can result in cardiac attest and lead to death. Palpitations, numbness, muscle pain, muscle weakness, nausea are some of the symptoms in patients suffering from severe hyperkalemia. Factors such as dehydration, chronic kidney disease (CKD), and type 1 diabetes are some of the main causes of hyperkalemia. Technavio’s market research analysts have predicted that with the introduction of diuretics, alkalinizing agents, and dialysis as some of the most promising approaches to treat hyperkalemia, the global hyperkalemia market will witness growth in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical drug development stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under phase III stage.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of hyperkalemia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
The hyperkalemia therapeutic assessment involves the development of majority of drugs for hyperkalemia in comparison to severe therapeutic assessment. Hyperkalemia can be controlled by medications.
According to this pipeline analysis report, some of the molecules that are currently in the drug development pipeline for hyperkalemia are being developed for the potassium binder mechanism of action. Potassium binder are administered orally or by retention enema for hyperkalemia.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.